This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Zinc Carnosine on Intestinal Permeability in Healthy Volunteers

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2005 by Imperial College London.
Recruitment status was:  Recruiting
Wexham GI Trust
Information provided by:
Imperial College London Identifier:
First received: September 7, 2005
Last updated: July 16, 2007
Last verified: September 2005
Zinc carnosine is a food supplement which is available in the health food shops. The investigators wish to see if it can reduce intestinal swelling in people who take non-steroidal anti-inflammatory (anti-swelling) drugs (NSAIDs).

Condition Intervention Phase
Healthy Drug: Zinc carnosine Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: Use of Zinc Carnosine on Intestinal Permeability in Healthy Volunteers Taking Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Further study details as provided by Imperial College London:

Primary Outcome Measures:
  • Effect of zinc carnosine in reducing the gut damage caused by non-steroidal anti-inflammatory drugs

Secondary Outcome Measures:
  • Differences in dyspepsia score
  • Differences in faecal calprotectin

Estimated Enrollment: 12
Study Start Date: May 2005

Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Aged 18-35 years

Exclusion Criteria:

  • Conditions known to alter intestinal permeability, eg previous bowel surgery, celiac disease
  • Conditions where NSAIDs are contraindicated, eg asthma, renal failure, heart failure
  • Diabetes
  • Any other serious illness
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00149149

Contact: Asif Mahmood, MD 02083838067

United Kingdom
Imperial College Recruiting
London, United Kingdom, W12 0NN
Contact: Asif Mahmood, MD    02083838067   
Sub-Investigator: Asif Mahmood, MRCP         
Principal Investigator: Raymond Playford, FRCP, PhD         
Sponsors and Collaborators
Imperial College London
Wexham GI Trust
Principal Investigator: Raymond Playford, MD, PhD Imperial College London
  More Information Identifier: NCT00149149     History of Changes
Other Study ID Numbers: 05/Q0408/19
Study First Received: September 7, 2005
Last Updated: July 16, 2007

Keywords provided by Imperial College London:
Reduction in NSAID related gut damage

Additional relevant MeSH terms:
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Trace Elements
Growth Substances processed this record on June 21, 2017